Amazon is making a serious move into the weight loss drug market. On Tuesday, the company unveiled a GLP-1 management program through Amazon One Medical, its primary care arm, bundling obesity treatment with pharmacy fulfillment and virtual care visits.
Amazon One Medical launched a national GLP-1 weight-loss program, offering injectable treatments starting at $299 per month and oral options starting at $149 per month.$HIMS pic.twitter.com/W1sEf30uKr
— Wall St Engine (@wallstengine) April 21, 2026
The program offers access to branded medications including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Insured patients can access oral GLP-1 drugs starting at $25 per month. Without insurance, oral options start at $149/month, while injectables like Wegovy and Zepbound begin at $299/month.
Those prices are broadly in line with the current market. But Amazon’s real pitch is convenience — same-day delivery backed by its logistics network and a seamless care journey from screening to prescription renewal.
Tanvi Patel, VP and GM of Amazon Pharmacy, said the goal is to make it easier for patients to “stay on those medications because they are delivered reliably directly to patients.”
The program is live across the U.S. and positions weight management as a long-term chronic condition, not a one-time prescription. It includes pre-visit screening, structured consultations, follow-up visits, and evidence-based treatment protocols.
On-demand prescription renewals are also available, starting at $29 for a message consultation and $49 for video care. Amazon plans to expand same-day delivery to 4,500 cities by the end of 2026.
The announcement hit Hims & Hers Health hard. HIMS dropped as much as 6% in pre-market trading, though losses narrowed through the session. The reaction reflects growing concern about Amazon crowding into the low-cost GLP-1 space that HIMS has been leaning into.
The timing is uncomfortable for HIMS. The company has been shifting focus toward branded obesity drugs — the more expensive end of the market — just as Amazon rolls out a competing bundled service. Bank of America has warned this could deal a 31% blow to HIMS’s GLP-1 franchise.
Other names tied to the obesity drug space also moved lower on Tuesday, including Viking Therapeutics (VKTX), Amgen (AMGN), and Septerna (SEPN).
This isn’t Amazon’s first step in the GLP-1 space. In January, it launched same-day delivery for Novo Nordisk’s Wegovy obesity pill. In April, it added same-day delivery for Eli Lilly’s new weight-loss pill, Foundayo, through its digital pharmacy.
Tuesday’s launch pulls those threads together into one integrated program — primary care, pharmacy, and virtual visits under a single roof.
On Wall Street, AMZN holds a Strong Buy consensus from 45 analysts — 42 Buys and 3 Holds. The average price target of $286.74 points to roughly 13% upside from current levels.
AMZN stock was up around 1% following the announcement.
The post Amazon (AMZN) Stock Rises as GLP-1 Launch Sends HIMS Stock Tumbling 6% appeared first on CoinCentral.
